Key result
Sacubitril-valsartan in HFrEF is linked to ~2-fold better conduit vessel function and increased functional capacity.
Why the study?
Does sacubitril-valsartan improve conduit vessel function, functional capacity, and inflammation in patients with heart failure with reduced ejection fraction?
Observational
Does sacubitril-valsartan improve conduit vessel function, functional capacity, and inflammation in patients with heart failure with reduced ejection fraction?
Sacubitril-valsartan improves endothelial function, functional capacity, and inflammatory markers in HFrEF patients, providing mechanistic insights into its clinical benefits.
May extend mechanistic insights into sacubitril-valsartan in HFrEF; hypothesis-generating and should not change practice without RCTs.
We observed an approximately twofold improvement in conduit vessel function (brachial artery FMD), increased functional capacity (6MWT distance), and a reduction in inflammation (TNF-α and IL-18) following 3 mo of sacubitril-valsartan therapy. These findings provide important new information concerning the physiological mechanisms by which this new drug class provokes favorable changes in HFrEF pathophysiology.
No takes yet. Share an insight, caveat, or question.
Bunsawat et al. (2020) conducted an observational in heart failure with reduced ejection fraction (HFrEF). sacubitril-valsartan was evaluated on conduit vessel function (brachial artery FMD), functional capacity (6MWT distance), and inflammation (TNF-α and IL-18). Sacubitril-valsartan therapy for 3 months resulted in an approximately twofold improvement in conduit vessel function, increased functional capacity, and reduced inflammation in HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: